Literature DB >> 27369872

Decompressive Hemicraniectomy in the Age of Personalized Medicine.

Michael N Diringer1.   

Abstract

Mesh：

Year:  2016        PMID： 27369872     DOI： 10.1007/s12028-016-0295-1

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN： 1541-6933            Impact factor:   3.210


× No keyword cloud information.
  11 in total

1.  Initial Conservative Management of Severe Hemispheric Stroke Reduces Decompressive Craniectomy Rates.

Authors:  Paul T Akins; Yekaterina V Axelrod; Syed T Arshad; Kern H Guppy
Journal:  Neurocrit Care       Date:  2016-08       Impact factor: 3.210

2.  Cranioplasty after decompressive hemicraniectomy: underestimated surgery-associated complications?

Authors:  Dorothee Wachter; Kim Reineke; Timo Behm; Veit Rohde
Journal:  Clin Neurol Neurosurg       Date:  2012-12-27       Impact factor: 1.876

3.  Middle cerebral artery territory infarction and early brain swelling: progression and effect of age on outcome.

Authors:  E F Wijdicks; M N Diringer
Journal:  Mayo Clin Proc       Date:  1998-09       Impact factor: 7.616

4.  The Role of Osmotic Therapy in Hemispheric Stroke.

Authors:  C J Ong; S G Keyrouz; M N Diringer
Journal:  Neurocrit Care       Date:  2015-10       Impact factor: 3.210

5.  Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials.

Authors:  Katayoun Vahedi; Jeannette Hofmeijer; Eric Juettler; Eric Vicaut; Bernard George; Ale Algra; G Johan Amelink; Peter Schmiedeck; Stefan Schwab; Peter M Rothwell; Marie-Germaine Bousser; H Bart van der Worp; Werner Hacke
Journal:  Lancet Neurol       Date:  2007-03       Impact factor: 44.182

6.  Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial.

Authors:  Jeannette Hofmeijer; L Jaap Kappelle; Ale Algra; G Johan Amelink; Jan van Gijn; H Bart van der Worp
Journal:  Lancet Neurol       Date:  2009-03-05       Impact factor: 44.182

7.  Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design.

Authors:  Kevin N Sheth; Jordan J Elm; Lauren A Beslow; Gordon K Sze; W Taylor Kimberly
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

8.  Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial.

Authors:  Eric Jüttler; Stefan Schwab; Peter Schmiedek; Andreas Unterberg; Michael Hennerici; Johannes Woitzik; Steffen Witte; Ekkehart Jenetzky; Werner Hacke
Journal:  Stroke       Date:  2007-08-09       Impact factor: 7.914

9.  Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial).

Authors:  Katayoun Vahedi; Eric Vicaut; Joaquim Mateo; Annie Kurtz; Mikael Orabi; Jean-Pierre Guichard; Carole Boutron; Gregory Couvreur; François Rouanet; Emmanuel Touzé; Benoît Guillon; Alexandre Carpentier; Alain Yelnik; Bernard George; Didier Payen; Marie-Germaine Bousser
Journal:  Stroke       Date:  2007-08-09       Impact factor: 7.914

10.  Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke.

Authors:  Eric Jüttler; Andreas Unterberg; Johannes Woitzik; Julian Bösel; Hemasse Amiri; Oliver W Sakowitz; Matthias Gondan; Petra Schiller; Ronald Limprecht; Steffen Luntz; Hauke Schneider; Thomas Pinzer; Carsten Hobohm; Jürgen Meixensberger; Werner Hacke
Journal:  N Engl J Med       Date:  2014-03-20       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.